Targeted cancer treatment can improve patient outcomes two- to three-fold. Genetic biomarker testing helps oncologists identify targeted treatments based on tumor DNA analysis. Canexia Health’s genomic testing solutions, including assays and concise reporting, provide cancer professionals with insights to aid targeted treatment decisions.
After a patient sample is received, report turnaround is 10 days. This turnaround time allows oncologists to implement effective treatment plans within a meaningful timeframe that could have a significant impact on a patient’s clinical outcome.
In Canada, the Access to Cancer Testing and Treatment program provides high quality cancer genomic testing to patients with metastatic or recurrent lung cancer. Imagia Canexia Health has expanded geographic access to this testing program which can help oncologists direct therapy selection and clinical trial options. The test is currently offered at no cost to lung cancer patients in Canada and breast cancer patients in Quebec.
Imagia Canexia Health’s Find It & Fusions panels detect mutations and gene fusion events in solid tumor tissue. Tissue profiling can be used to help inform treatment decisions or predict progression of cancer based on somatic mutations found in the tumor.
Imagia Canexia Health’s Follow It panel detects mutations in plasma. Plasma profiling (a type of liquid biopsy) can be used to help tailor treatment, monitor cancer progression, or detect treatment resistance.
Each comprehensive report includes detailed results as well as therapeutic recommendations and expertly curated clinical trials. Our insights can help you make more informed treatment decisions.
If you think Canexia’s solution might be appropriate for your patients and organization, please contact us for more information.